cyclophilin


Also found in: Acronyms, Encyclopedia, Wikipedia.

cyclophilin

Any of a family of high-affinity cyclosporin A-binding proteins (cyclophilin A [MIM:123840]; cyclophilin B [MIM:123841]; cyclophilin C [MIM:123842]) that catalyse cis-trans isomerisations. Cyclophilin is the trivial name for peptidylprolyl isomerase, EC 5.2.1.8 (peptidylproline cis-trans-isomerase).
References in periodicals archive ?
For more than two decades Berk has studied cyclophilin A, showing how it promotes destructive forces in blood vessels and how it's central to the forces that contribute to cardiovascular diseases like atherosclerosis and heart attack.
The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition.
The company, which is located in Research Triangle Park, North Carolina, is also developing a proprietary internal pipeline based on cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.
In the poster presentation entitled, "In vitro Models for Assessing the Relative Risk of Hyperbilirubinemia Associated with Cyclophilin Inhibitor Therapy," SCYNEXIS examined the qualitative relationship between drug-mediated inhibition of multidrug resistance protein 2 (MRP2) and treatment-associated hyperbilirubinemia in a rodent hepatocyte model.
Resistance Selection Following 15 Days of Monotherapy with SCY-635 a Non-immunosuppressive Cyclophilin Inhibitor with Potent Anti-HCV Activity," Thursday, April 15, 2010, 17:45 to 18:00 CET.
Only bladder washings with a cyclophilin A copy number [greater than or equal to] 5 were included in the analyses because lower numbers indicated insufficient yield of cells from the bladder washings and thus unreliable quantification of survivin mRNA copy number.
The Company, which is located in Research Triangle Park, North Carolina, is also focused on developing a proprietary internal pipeline based on cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.
This impact probably depends on the equilibrium between uptake, cyclophilin binding, P-glycoprotein-dependent excretion, and probably other factors related to each cell type.
SCY-635's novel cyclophilin inhibitor method-of-action, when used as part of a combination therapy regimen, may help overcome resistance and could also increase the percentage of patients that achieve a sustained virological response to therapy.
These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes - protease (partnered with Abbott), NS5A (partnered with Novartis), nucleotide polymerase, and a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin.
A similar approach was conducted for the cyclophilin housekeeping gene (data not shown), and final results were expressed as the ratio CYP2E1 cDNA copies/[micro]g of total RNA or as the ratio CYP2E1 cDNA copies/ cyclophilin cDNA copies.
Presentation at AASLD: Tuesday, November 3, 8:00 AM - 1:00 PM ET: HCV Therapy: Preclinical and Clinical Development Session Abstract 1595 entitled "Antiviral Activity of the Non-Immunosuppressive Cyclophilin Inhibitor SCY-635 in Combination with Investigational and Approved Anti-HCV Agents" will be presented by SCYNEXIS.